AQST-109 is under clinical development by Aquestive Therapeutics and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AQST-109’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine (AQST-109) is under development for the treatment of allergic reactions including anaphylaxis. It is administered through sublingual route as film. The drug candidate is being developed based on PharmFilm technology.
Aquestive Therapeutics overview
Aquestive Therapeutics (Aquestive), is a Pharmaceutical company. It offers drug products. The company offers products that includes sympazan, a film formulation of clobazamor for treating seizures associated with Lennox-Gastaut syndrome (LGS); suboxone for the treatment of opioid dependence; zuplenz for the treatment of nausea and vomiting; and diazepam. It also provides nutraceuticals, packaging solutions, and consumer products. Aquestive provides PharmFilm, a drug delivery platform that delivers existing prescription products directly to the bloodstream. The company collaborates with other pharmaceutical companies for the development and commercialization of its pharmaceutical products. The company has manufacturing facility in Indiana, the US. Aquestive Therapeutics is headquartered in Warren, New Jersey, the US
For a complete picture of AQST-109’s drug-specific PTSR and LoA scores, buy the report here.